OpenLB
Open Library of Bioscience
Advanced Search
PeerJ
2023;11 e15277.

Side-effects of hyperthermic intraperitoneal chemotherapy in patients with gastrointestinal cancers.

Jiyun Hu, Zhenxing Wang, Xinrun Wang, Shucai Xie
Author Information
  1. Jiyun Hu: Department of Critical Care Medicine, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China. ORCID
  2. Zhenxing Wang: Department of Hepatobiliary Surgery, Haikou People's Hospital/Affiliated Haikou Hospital of Xiangya Medical College, Central South University, Haikou, Hainan, China.
  3. Xinrun Wang: Department of Critical Care Medicine, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  4. Shucai Xie: Department of Critical Care Medicine, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China. ORCID
PMID: 37138820 DOI: 10.7717/peerj.15277

Abstract

Background: Hyperthermic intraperitoneal chemotherapy (HIPEC) produces unwanted side-effects that are mainly caused by chemotherapeutic drugs in the treatment of gastrointestinal (GI) cancers, and these effects have not been systematically summarized. The aim of this article was to provide a comprehensive overview of the side-effects of HIPEC for GI cancers and propose practical strategies for adverse event management.
Methodology: PubMed, Web of Science, and the Cochrane Library were systematically searched for side-effects of HIPEC in GI cancers prior to October 20, 2022. A total of 79 articles were included in this review.
Results: Adverse events, such as enterocutaneous digestive fistulas, GI tract perforation, neutropenia, postoperative bleeding, ventricular tachycardia, hyperglycemia, hypocalcemia, renal impairment, encapsulating peritoneal sclerosis, scrotal ulceration, and sarcopenia were described, and their clinical management was discussed. These side-effects involve the digestive, hematopoietic, circulatory, metabolic, and urinary systems. Effective methods for adverse event management included an expert multidisciplinary team, replacing chemotherapy drugs, using Chinese medicine, and careful preoperative assessments.
Conclusion: The side-effects of HIPEC are frequent and can be minimized by several effective methods. This study proposes practical strategies for adverse event management of HIPEC to assist physicians in choosing the optimal treatment method.

Keywords

Colorectal cancer Gastric cancer Gastrointestinal cancers Hyperthermic intraperitoneal chemotherapy Side effects

References

  1. J Clin Oncol. 2003 Oct 15;21(20):3737-43 [PMID: 14551293]
  2. Cancer Chemother Pharmacol. 2018 Apr;81(4):697-704 [PMID: 29429054]
  3. Ann Surg Oncol. 2009 Aug;16(8):2181-7 [PMID: 19475451]
  4. Biomaterials. 2016 Feb;79:46-55 [PMID: 26695116]
  5. Ann Surg. 2013 Jun;257(6):1065-71 [PMID: 23299520]
  6. J Gastrointest Cancer. 2015 Mar;46(1):60-3 [PMID: 25403827]
  7. Adv Mater. 2013 Jul 26;25(28):3869-80 [PMID: 24048973]
  8. Eur Rev Med Pharmacol Sci. 2012 Jun;16(6):737-42 [PMID: 22913203]
  9. ScientificWorldJournal. 2013 Mar 25;2013:720858 [PMID: 23589707]
  10. Clin Pharmacokinet. 2004;43(2):131-43 [PMID: 14748621]
  11. Ann Surg Oncol. 2020 Jan;27(1):124-131 [PMID: 31073912]
  12. Eur J Surg Oncol. 2016 Feb;42(2):219-23 [PMID: 26278017]
  13. Am J Surg. 2022 Feb;223(2):331-338 [PMID: 33832737]
  14. Ann Oncol. 2019 Mar 1;30(3):431-438 [PMID: 30689702]
  15. J BUON. 2015 May;20 Suppl 1:S60-3 [PMID: 26051334]
  16. Oncology (Williston Park). 2015 Jul;29(7):515-21 [PMID: 26178339]
  17. Cancer. 1994 Apr 15;73(8):2048-52 [PMID: 8156509]
  18. Biosci Trends. 2015 Feb;9(1):16-34 [PMID: 25787906]
  19. J Surg Oncol. 2014 Dec;110(8):970-5 [PMID: 25171494]
  20. BMC Complement Altern Med. 2012 Sep 19;12:160 [PMID: 22992293]
  21. Ann Surg Oncol. 2015 Dec;22 Suppl 3:S873-9 [PMID: 26100819]
  22. Drug Deliv. 2019 Dec;26(1):898-917 [PMID: 31526065]
  23. BMC Surg. 2014 Aug 27;14:57 [PMID: 25160862]
  24. World J Gastrointest Oncol. 2010 Jan 15;2(1):19-30 [PMID: 21160813]
  25. ANZ J Surg. 2019 Oct;89(10):E468-E469 [PMID: 30173413]
  26. Eur J Surg Oncol. 2006 Aug;32(6):682-5 [PMID: 16631341]
  27. Lancet Oncol. 2020 Jul;21(7):923-934 [PMID: 32511981]
  28. Eur J Surg Oncol. 2019 Mar;45(3):383-388 [PMID: 30409441]
  29. J Minim Access Surg. 2016 Jan-Mar;12(1):86-9 [PMID: 26917929]
  30. Immunopharmacol Immunotoxicol. 2008;30(4):771-82 [PMID: 18686097]
  31. World J Gastroenterol. 2018 Mar 14;24(10):1072-1083 [PMID: 29563752]
  32. World J Gastroenterol. 2016 Jan 21;22(3):1114-30 [PMID: 26811651]
  33. Int J Colorectal Dis. 2022 Jan;37(1):17-33 [PMID: 34626208]
  34. Surg Oncol. 2016 Sep;25(3):315-20 [PMID: 27566038]
  35. J Am Coll Surg. 2018 Apr;226(4):434-443 [PMID: 29331663]
  36. Oncol Rep. 2006 Sep;16(3):631-41 [PMID: 16865266]
  37. J Clin Oncol. 2019 Nov 1;37(31):2892-2898 [PMID: 31545663]
  38. CA Cancer J Clin. 2021 May;71(3):209-249 [PMID: 33538338]
  39. Oncogene. 2016 Jan 14;35(2):261-8 [PMID: 25867070]
  40. Anaesthesia. 2009 Oct;64(10):1134-6 [PMID: 19735407]
  41. Cancer Biol Ther. 2020 Aug 2;21(8):726-732 [PMID: 32644887]
  42. Horm Metab Res. 2020 Sep;52(9):689-690 [PMID: 32770533]
  43. Surg Oncol Clin N Am. 2003 Jul;12(3):689-701 [PMID: 14567025]
  44. Lancet Oncol. 2021 Feb;22(2):162-164 [PMID: 33476594]
  45. Ann Surg Oncol. 2008 Sep;15(9):2426-32 [PMID: 18521686]
  46. Cancer Res. 1980 Feb;40(2):256-60 [PMID: 6766084]
  47. Surg Today. 2003;33(3):232-6 [PMID: 12658394]
  48. Ann Surg Oncol. 2018 Mar;25(3):655-659 [PMID: 29204776]
  49. Cutis. 2019 Jul;104(1):E1-E3 [PMID: 31487345]
  50. Ann Surg Oncol. 2020 Jan;27(1):171-178 [PMID: 30963398]
  51. Front Pharmacol. 2021 Apr 12;12:633447 [PMID: 33912050]
  52. Cancer. 2001 Jul 1;92(1):71-6 [PMID: 11443611]
  53. Eur J Surg Oncol. 2020 Apr;46(4 Pt A):577-581 [PMID: 31677939]
  54. Farm Hosp. 2012 Mar-Apr;36(2):60-7 [PMID: 21514864]
  55. Ann Surg Oncol. 2015 Oct;22(11):3625-31 [PMID: 25672564]
  56. J Surg Oncol. 2008 Sep 15;98(4):247-52 [PMID: 18726886]
  57. Nat Rev Gastroenterol Hepatol. 2018 Nov;15(11):659-670 [PMID: 29970888]
  58. Tumori. 1999 Jan-Feb;85(1):41-6 [PMID: 10228496]
  59. Nat Rev Gastroenterol Hepatol. 2018 Dec;15(12):721-737 [PMID: 30185915]
  60. Support Care Cancer. 2018 Jan;26(1):7-20 [PMID: 28939926]
  61. Gastroenterology. 2020 Jul;159(1):335-349.e15 [PMID: 32247694]
  62. Support Care Cancer. 2020 Jun;28(6):2745-2752 [PMID: 31712951]
  63. Int J Hyperthermia. 2019;36(1):493-498 [PMID: 30935256]
  64. Int J Surg. 2019 Apr;64:5-9 [PMID: 30772524]
  65. PLoS Biol. 2016 Aug 19;14(8):e1002533 [PMID: 27541692]
  66. Ann Surg Oncol. 2022 Mar;29(3):2077-2086 [PMID: 34665362]
  67. Eur J Surg Oncol. 2016 Jun;42(6):909-10 [PMID: 26965304]
  68. Cancer Treat Rep. 1978 Jan;62(1):1-11 [PMID: 626987]
  69. Oncology. 1999;57(2):106-14 [PMID: 10461056]
  70. Lancet Gastroenterol Hepatol. 2021 Jun;6(6):498-509 [PMID: 33743198]
  71. Eur J Cancer. 2017 Jul;79:1-14 [PMID: 28456089]
  72. World J Surg Oncol. 2017 Feb 20;15(1):49 [PMID: 28219391]
  73. Surg Oncol. 2018 Sep;27(3):456-461 [PMID: 30217302]
  74. J Natl Compr Canc Netw. 2015 Nov;13(11):1383-93 [PMID: 26553767]
  75. Ann Surg Oncol. 2006 May;13(5):635-44 [PMID: 16523363]
  76. Surg Infect (Larchmt). 2018 Aug/Sep;19(6):618-621 [PMID: 30044187]
  77. Hepatogastroenterology. 1989 Apr;36(2):75-8 [PMID: 2499527]
  78. Am J Physiol Renal Physiol. 2005 Mar;288(3):F433-42 [PMID: 15692055]
  79. Int J Clin Oncol. 2020 May;25(5):984-994 [PMID: 31915944]
  80. Eur J Surg Oncol. 2006 Aug;32(6):593-6 [PMID: 16603332]
  81. J Surg Oncol. 2010 Jun 1;101(7):634-6 [PMID: 20461773]

MeSH Term

Humans
Hyperthermic Intraperitoneal Chemotherapy
Hyperthermia, Induced
Gastrointestinal Neoplasms
Combined Modality Therapy
Antineoplastic Combined Chemotherapy Protocols
Intestinal Fistula
Drug-Related Side Effects and Adverse Reactions
Systematic Review Journal Article Research Support, Non-U.S. Gov't
Article has an altmetric score of 1

Word Cloud

Created with Highcharts 10.0.0HIPECside-effectscancerschemotherapyGImanagementintraperitonealadverseeventHyperthermicdrugstreatmentgastrointestinaleffectssystematicallypracticalstrategiesincludeddigestivemethodscancerBackground:producesunwantedmainlycausedchemotherapeuticsummarizedaimarticleprovidecomprehensiveoverviewproposeMethodology:PubMedWebScienceCochraneLibrarysearchedpriorOctober202022total79articlesreviewResults:AdverseeventsenterocutaneousfistulastractperforationneutropeniapostoperativebleedingventriculartachycardiahyperglycemiahypocalcemiarenalimpairmentencapsulatingperitonealsclerosisscrotalulcerationsarcopeniadescribedclinicaldiscussedinvolvehematopoieticcirculatorymetabolicurinarysystemsEffectiveexpertmultidisciplinaryteamreplacingusingChinesemedicinecarefulpreoperativeassessmentsConclusion:frequentcanminimizedseveraleffectivestudyproposesassistphysicianschoosingoptimalmethodSide-effectshyperthermicpatientsColorectalGastricGastrointestinalSide

Similar Articles

Cited By